Pursuant to regulation 33(3)(d) of SEBI LODR Regulations, 2015 we are pleased to submit the financials for the year ended on 31st March, 2026
SYNCOMF · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Syncom Formulations India Ltd reported strong annual results for FY2025-26. Standalone revenue from operations grew ~7.8% to Rs. 51,754 Lacs from Rs. 48,004 Lacs in the prior year. Consolidated PAT surged ~55% to Rs. 7,644 Lacs (EPS 0.81) vs Rs. 4,943 Lacs (restated EPS 0.52) the previous year. The company corrected its EPS calculation methodology — previously using Total Comprehensive Income — to now comply with Ind AS 33 (using PAT attributable to equity shareholders), resulting in restatement of all prior period EPS figures. The auditor issued an unmodified opinion with an emphasis of matter on the EPS restatement. Borrowings reduced significantly from Rs. 458 Lacs to Rs. 147 Lacs, and operating cash flow was healthy at Rs. 5,808 Lacs. The company recognized an incremental cost of Rs. 87.81 Lacs due to new labour codes effective November 2025.
Strong bottom-line growth of ~55% with clean audit opinion and reduced debt. The EPS restatement is an accounting correction rather than a business issue, but investors should note the restated prior-year EPS was lower than originally reported.